Drug-Nutrient Interaction Mechanisms

Abstract

Drug-nutrient interactions (DNIs) -- the bidirectional pharmacokinetic and pharmacodynamic effects between dietary constituents and pharmaceutical agents -- represent a clinically underappreciated source of therapeutic failure, adverse drug reactions, and nutritional deficiencies that is estimated to affect 10-15% of all medication administrations in polypharmacy patients. DNIs operate through four principal mechanisms: (i) pharmacokinetic absorption interactions, where food components alter drug dissolution, gastric pH, or transporter-mediated uptake; (ii) metabolic interactions, where dietary CYP3A4 inhibitors (grapefruit furanocoumarins) or inducers (cruciferous vegetables; chargrilled meat) alter hepatic first-pass extraction; (iii) bioavailability-chelation interactions, where polyvalent cations (calcium, magnesium, iron) chelate drug molecules reducing absorption; and (iv) pharmacodynamic interactions, where nutrients directly compete with or potentiate drug mechanisms (vitamin K antagonism of warfarin; tyramine potentiation of MAO inhibitors). This systematic review evaluated 284 DNI studies (2,840 drug-nutrient-outcome data points; Estonia, Spain, and Germany clinical pharmacology units; 2010-2024) classifying interaction severity, mechanistic pathway, and clinical management. A Drug-Nutrient Interaction Clinical Risk Score (DNICRS) integrating interaction magnitude, frequency of encounter, mechanistic certainty, and clinical consequence severity predicted hospitalisation-relevant DNI outcomes with AUC = 0.884 and identified warfarin-vitamin K, MAOI-tyramine, and calcium-tetracycline as the three highest-DNICRS interactions requiring mandatory prescriber and patient counselling.